When people start Wegovy, Ozempic or Mounjaro, they naturally focus on the number on the scale. But one of the most significant — and often underappreciated — benefits of GLP-1 medications is their effect on visceral fat. This is the fat that most strongly predicts your risk of heart disease, type 2 diabetes and a range of other serious conditions. And GLP-1 drugs appear to target it with particular effectiveness.

What exactly is visceral fat — and why is it different?

Not all fat is created equal. The fat you can pinch on your belly, thighs or upper arms is called subcutaneous fat — it sits just beneath the skin. While excess subcutaneous fat has its own health implications, it is relatively metabolically inactive.

Visceral fat is different. It sits deep inside the abdominal cavity, packed around your organs — the liver, pancreas, intestines and kidneys. You cannot see it or feel it from the outside, and a person can have dangerous levels of visceral fat even at a relatively "normal" body weight.

What makes visceral fat so harmful is that it behaves almost like an active organ. It continuously releases inflammatory cytokines (proteins that trigger inflammation), free fatty acids that flood the liver, and hormones that disrupt insulin signalling. This makes visceral fat a primary driver of:

In short, visceral fat is the fat that does the most damage — and the fat most worth reducing.

Do GLP-1 medications specifically target visceral fat?

Yes — and the evidence is compelling. Clinical imaging studies using CT and MRI scans show that people taking semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) lose visceral fat at a proportionally greater rate than their overall fat loss.

The landmark STEP-1 trial (published in NEJM, 2021), which studied semaglutide 2.4 mg over 68 weeks, showed an average weight loss of 14.9% — accompanied by a 13.5 cm reduction in waist circumference. Since waist circumference is a proxy for visceral fat, this signals a profound reduction in deep abdominal fat.

The SURMOUNT-1 trial (tirzepatide, NEJM, 2022) showed even stronger results: up to 20.9% average weight loss, with waist reductions of up to 16 cm. Independent imaging analyses from related studies confirm that visceral fat depots shrink disproportionately compared to subcutaneous fat stores.

A 2022 review published in PMC (PMC9293358) confirmed that GLP-1 receptor agonists reduce visceral adiposity beyond what would be predicted from caloric restriction alone, suggesting the medications may have direct effects on fat tissue.

How do GLP-1 drugs reduce visceral fat?

Several mechanisms work together:

How do you know if you have too much visceral fat?

The simplest screening tool is a tape measure. The WHO guidelines suggest concern when:

Measure at the midpoint between your lowest rib and the top of your hip bone, breathing normally. The waist-to-hip ratio is another useful metric: above 0.90 for men and 0.85 for women indicates elevated visceral fat risk.

For a more precise assessment, a DEXA scan (dual-energy X-ray absorptiometry) or abdominal CT/MRI can directly quantify visceral fat volume — though these are typically used in research or clinical settings rather than routine care.

Remember: you cannot judge visceral fat from appearance alone. A person with a "normal" BMI can carry dangerous levels of visceral fat if they are physically inactive, eat a poor diet, sleep badly or are under chronic stress.

What lifestyle changes accelerate visceral fat loss?

GLP-1 medications are a powerful tool — but combining them with targeted lifestyle changes produces the best results. Here is what the evidence shows:

Strength training is especially effective

Resistance exercise specifically targets visceral fat. Multiple studies show that strength training reduces visceral adiposity even without significant changes in body weight. Aim for at least 2–3 sessions per week. You do not need a gym — bodyweight exercises (squats, lunges, push-ups, planks) are a solid starting point.

Poor sleep increases visceral fat

This connection surprises many people. Studies consistently show that sleeping fewer than 6 hours per night is associated with significantly greater visceral fat accumulation — independent of diet or exercise. Prioritise 7–9 hours of quality sleep. Poor sleep raises cortisol, which directly promotes visceral fat storage.

Alcohol — especially beer — accumulates around the organs

Alcohol is metabolised in the liver, and excess alcohol consumption directly promotes visceral fat storage. The so-called "beer belly" is a real phenomenon: abdominal fat from alcohol is predominantly visceral, not subcutaneous. Reducing alcohol is one of the most effective and immediate dietary changes you can make.

Chronic stress drives visceral fat through cortisol

The stress hormone cortisol tells the body to store energy as visceral fat. Chronic psychological stress — work pressure, relationship problems, financial worry — elevates cortisol for prolonged periods and can significantly increase visceral fat even in people who eat well and exercise. Mindfulness, adequate rest, social connection and regular physical activity all help manage cortisol levels.

The good news: visceral fat responds faster than subcutaneous fat

Here is something encouraging: visceral fat is actually more metabolically active and more responsive to intervention than subcutaneous fat. When you start GLP-1 medication, adopt a better diet or begin exercising, visceral fat is typically the first to mobilise. You may notice your waist shrinking and your trousers fitting better before the scale shows dramatic changes — because you are losing the fat that matters most.

A 2023 study (PubMed: 37553198) confirmed that elevated visceral adiposity increases metabolic risk even at normal weight — and that targeted reduction produces rapid improvements in insulin sensitivity, blood pressure and inflammatory markers, often within weeks of meaningful visceral fat loss.

Putting it all together

Visceral fat is the most metabolically dangerous fat in your body — and one of the strongest predictors of serious disease. The excellent news for people taking Wegovy, Ozempic or Mounjaro is that these medications appear to preferentially reduce visceral fat, delivering health benefits that go well beyond what the scale alone can show.

Track your waist circumference alongside your weight. Combine your medication with strength training, quality sleep, reduced alcohol and stress management to maximise results. And remember that even a modest reduction in visceral fat can bring meaningful improvements in blood sugar, blood pressure and cardiovascular risk.

Always speak to your doctor about the best approach for your individual situation.

Sources